Personalis' NeXT Personal Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
Is Personalis (NASDAQ:PSNL) Weighed On By Its Debt Load?
Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires?
Personalis to Announce First Quarter 2025 Financial Results
Personalis and Academic Partners to Present Latest Data on Ultrasensitive CtDNA Test for Residual Cancer and Recurrence Detection
Needham Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7
What 5 Analyst Ratings Have To Say About Personalis
Personalis Price Target Maintained With a $7.00/Share by Needham
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
The Price Is Right For Personalis, Inc. (NASDAQ:PSNL) Even After Diving 40%
Craig-Hallum Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $8
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7
BTIG Reaffirms Their Buy Rating on Personalis (PSNL)
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Personalis Initiated at Buy by Craig-Hallum
Craig-Hallum Initiates Coverage On Personalis With Buy Rating, Announces Price Target of $8
Craig Hallum Initiates Coverage on Personalis With Buy Rating, $8 Price Target
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $5
Hold Rating for Personalis: Balancing Strong Enterprise Sales and Future Uncertainties
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip